About Tumour Models Summit Malmö
The Nordic oncology landscape is rapidly advancing, driven by strong investment in precision medicine and advanced therapeutics. Sweden alone is projected to see its precision oncology market exceed USD 2 billion by 2030, underscoring the region’s accelerating demand for translationally relevant preclinical models. This surge in innovation makes the Nordics a critical arena for advancing tumour model development and improving preclinical decision‑making for next‑generation oncology assets.
Part of the world-renowned Tumor Models events series, the 2nd Tumour Models Summit Malmö returns as the must-attend meeting for preclinical, translational, discovery, pharmacology, and biology teams striving to refine model‑selection strategies. This is the opportune moment to dissect comparative in vitro, in vivo, and ex vivo system performance, evaluate model fidelity against clinical outcomes; and refine predictive workflows that improve R&D efficiency and systematically de‑risk oncology assets prior to IND‑enabling studies.
Explore the Agenda
Hear the latest preclinical and translational data on tumour modelling, and gain first-hand insight into innovations on modelling for in vitro, in vivo, complex in vitro and more across multiple modalities.
Partner With Us
Position yourself as the partner of choice amongst leading model developers and solution providers to ensure your brand is at the heart of biopharma deals and collaborations.
Join Nordic Oncology Industry Experts
Connect with preclinical, translational, discovery, pharmacology, and biology drug developers from the leading Nordic biopharma companies through focused presentations, panels, and networking designed to spark meaningful scientific and commercial conversations.